ROQUMEDIA
ROQUMedia:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005564/en/
FLOYD MAYWEATHER:
https://twitter.com/FloydMayweather/status/1517594581373648896?s=20&t=dEEnqLrQWsybIa81CA-JJA
Global Titans Fight Series announced the WORLD’S FIRST EVER NFT SPORTS event will give access to an exclusive livestream pay-per-view for NFT ticket holders. The Global Titans NFT tickets are considered a historic moment, where sports and tech fans take a giant leap forward, changing the way one interacts with live entertainment.
The NFT ticket will give access to watch Global Titans Dubai live online on May 14th , where an epic night of boxing on the helipad of the iconic Burj Al Arab Jumeirah hotel. The spectacular event boasts an explosive line-up including star champions Floyd Mayweather, Anderson Silva and many more.
A landmark moment for international sports, fans buying the NFT will also acquire a special Global Titans NFT ticket, that is highly collectable. More than an event ticket, NFT technology provides buyers with unique features such as future access, rewards and more – all that increase the value of its ownership long after the event.
Developing special technologies, ROQUMedia and Yakomoz Events, the founders of Global Titans, have teamed up with Web3 experts, MintGate for this NFT. Buyers will be able to watch the livestream of these inaugural fights directly from anywhere in the world without requiring access codes or passwords. NFT owners can simply connect their crypto wallets (such as MetaMask) for instant access.
Additionally, owners of this NFT will be able to unlock Limited Edition 3D collectibles, special video content and official media from the event.
There are two Global Titans NFT tickets now available to the public.
- 80,000 collectible NFTs with PPV access in the Polygon Matic or payable by credit card.
- Currently 10 highly exclusive ringside seat NFTs are available to attend this event in person.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream are available at www.globaltitans.com
“MintGate is hyper-focused on making digital ownership accessible to anyone in the world,” said Jonathan Dunlap (CEO). “To further this mission, we launched a revolutionary way to purchase a NFT directly with a credit card,” continued Matt Hoffman (CSO).
Robert Quirke, ROQUMedia (CEO) stated: “For many people, this will be the first time they will buy an NFT. We made sure to provide them with great value, by including exciting digital assets that can be traded and combined to watch the Floyd Mayweather fight livestream online. The live event on May 14th will be known as an international turning point where live sports and entertainment embraced the next generation of technology. The PPV tickets use the Polygon Blockchain & MATIC, as this offers fans the lowest gas fees, making them significantly more environmentally friendly.”
GLOBAL TITANS
Global Titans Dubai is the first in series of special boxing and MMA events which will be staged at iconic locations across four continents. Each main event is broadcast globally, featuring champion fighters and exclusive collectable NFT tickets.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream : www.globaltitans.com
MINTGATE
MintGate is a proven web3 platform for building membership-based communities and elevating the relationship between people and the brands they care about. We bring people closer to the future by unlocking the value of digital ownership.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005564/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom